Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeyPro2: Vemurafenib + Cobimetinib Beyond Progression in Melanoma
NCT03514901Phase 2Unknown
- Sponsor
- Intergruppo Melanoma Italiano
- Start
- Jun 2018
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib, cobimetinib in melanoma, sponsored by Intergruppo Melanoma Italiano. Status: unknown.
02
Drugs
vemurafenibcobimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03514901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03514901.